Executive summary
U.S. Patent 5,234,404 claims methods that use an “exercise simulating agent” with beta-adrenergic activity delivered by a closed-loop drug delivery device to elicit immediate cardiovascular responses and/or adaptive cardiovascular and metabolic responses comparable to those from aerobic activity. The claims are broad on the concept (exercise-mimicking via beta-adrenergic pharmacology under closed-loop control), medium on delivery modality (explicitly includes intravenous and transdermal iontophoretic closed-loop infusion), and narrow on chemical identity for certain dependent claims (specific substituent-defined formulae and salts). The patent’s enforceable claim scope, as drafted, is anchored by (i) the presence of a beta-adrenergic agent that is characterized by the claimed formula in the dependent claims, and (ii) the use of closed-loop control to maintain a predetermined range of physiological responses. Potential infringement risk for competitors turns on whether they (a) use the same or substitutable beta-adrenergic “exercise simulating” compounds and (b) implement responsive dose titration that meets the “closed loop” and “maintain predetermined range” limitations.
What does U.S. Patent 5,234,404 claim about beta-adrenergic “exercise simulating agents”?
At a high level, the patent combines three claim pillars:
- Pharmacology pillar: administration of an exercise simulating agent with beta-adrenergic activity intended to generate physiological effects similar to aerobic exercise.
- Control pillar: use of a closed loop drug delivery device that adjusts infusion based on monitoring of physiological responses.
- Outcome pillar: immediate cardiovascular responses and, in separate claim sets, adaptive cardiovascular and metabolic responses over time.
Claim set A: immediate cardiovascular response methods with closed-loop delivery (independent claim 1; method claim 6/7 set)
Claim 1:
- Method of eliciting immediate cardiovascular responses similar to those elicited by aerobic activity.
- Requires: administration of the beta-adrenergic exercise simulating agent by a closed loop drug delivery device.
Claim 6 (independent, framed as a workflow):
- Administer beta-adrenergic exercise simulating agent via a closed loop drug delivery device.
- Control infusion into the bloodstream to achieve a predetermined range of cardiovascular responses.
- Monitor the responses.
- Change infusion as required to maintain the range.
Claim 7 further requires that the agent comprises a compound of a claimed formula (dependent on claim 6’s closed-loop structure).
Claim set B: adaptive cardiovascular and metabolic response over a treatment window (claim 2)
Claim 2:
- Method of eliciting adaptive cardiovascular and metabolic responses similar to those elicited by aerobic activity.
- Requires administration of the beta-adrenergic exercise simulating agent via closed-loop transdermal iontophoretic infusion.
- Requires an explicit dosing schedule: 0.5 to 4.0 hours daily for 1 to 30 days.
This claim is narrower than claim 1 and 6 because it locks in the delivery modality (transdermal iontophoretic closed-loop infusion) and the time regimen.
Claim set C: disease state and delivery variants (claims 8-13)
Claim 8 (dependent on claim 7): predetermined response level includes reversible myocardial ischemia when coronary artery disease is present.
This introduces a clinically specific physiological target.
Claims 9-10 (dependent on claim 8):
- Closed-loop device includes intravenous drug delivery (claim 9).
- Closed-loop device includes transdermal iontophoretic device (claim 10).
This matters because the patent’s independent claim 6 is not limited to transdermal; instead, claims 9 and 10 add alternatives under the disease-specific framework of claim 8.
Claims 11-13 (dependent on claim 8 + focusing on chemical substitutions):
- Claim 11: agent has Z = hydroxy.
- Claims 12-13 then specify additional substituent sets (X1, X2, Y1, Y2, n).
These dependents tether infringement more tightly to the chemical formula variants.
Claim set D: increased contractility in depressed contractility (claim 14-15)
Claim 14:
- Method for increasing cardiac contractility in a mammal with depressed cardiac contractility.
- Requires administration of a compound of a defined formula (substituent rules included) or pharmaceutically acceptable addition salt.
Claim 15 narrows further: a specific substitution pattern (X1 = hydrogen, X2 = carbamoyl, Y1 = methyl, Y2 = hydrogen, n = 2).
Claim set E: adaptive effects similar to aerobic exercise using defined compounds (claim 16-19)
Claim 16:
- Method causing adaptive effects similar to adaptive responses of aerobic exercise.
- Requires administration of a compound of a defined formula (substitution framework in claim text) or acceptable acid addition salt.
Claims 17-19 lock in specific substitution patterns (X1/X2/Y1/Y2/n combinations).
How broad are the claims: concept scope vs chemical and device scope?
1) Scope of “beta-adrenergic activity”
The independent claims (1 and 6/7) require an “exercise simulating agent with beta adrenergic activity.” The supplied claim text treats “beta adrenergic activity” functionally, while some dependent claims restrict to compounds defined by formula. Practically, infringement analysis splits:
- If a competitor’s agent is not within the dependent formula limits, it may still potentially satisfy independent claims 1 or 6 if the “exercise simulating agent with beta adrenergic activity” limitation is met and the delivery is closed-loop with monitoring/titration.
- If the competitor uses a beta-adrenergic agent that matches the claimed formula structures, risk increases because dependents (7, 11-13, 14-15, 16-19) can be read more naturally onto specific chemical entities.
2) Scope of “exercise simulating agent”
“Exercise simulating agent” is a purpose/intended functional descriptor tied to outcomes “similar to those cardiovascular responses elicited by aerobic exercise.” That means the claim interpretation can pivot on what physiological effects are considered “similar.” However, the claim language repeatedly anchors similarity to specific categories:
- immediate cardiovascular responses (claim 1; claim 6/7)
- adaptive cardiovascular and metabolic responses (claim 2; claim 16)
- contractility increase in depressed contractility (claim 14)
From a claim construction standpoint, these are outcome-labeled limitations. A competitor can reduce risk by arguing their outcomes are not “similar” to aerobic exercise per the claim metrics, but the scope remains broad if any measurable overlap exists.
3) Scope of closed-loop delivery device
This is the most structurally differentiating element.
- Claim 1: administration via a closed loop drug delivery device.
- Claim 6: explicitly requires controlling infusion based on monitoring to keep the response within a predetermined range, then changing infusion to maintain the range.
Closed-loop limitations are often the main engineering battleground:
- Does the system monitor cardiovascular responses (or a proxy) in real time?
- Does it control infusion based on feedback and maintain a predetermined range?
- Is the feedback loop sufficiently automatic and responsive to meet “closed loop” as claimed?
Claims 2, 9-10 explicitly include intravenous drug delivery and transdermal iontophoretic device embodiments, strengthening enforceability across common administration routes when feedback control is used.
Which claim elements are most likely to be litigated for infringement?
Immediate response workflow (claims 6-7)
The highest-friction limitations in a typical infringement dispute are:
- whether the system uses a closed-loop approach that changes dosing in response to monitored responses; and
- whether the physiological target meets “predetermined range” maintenance.
A competitor using fixed-rate dosing or periodic titration without real-time feedback typically has lower risk against claim 6’s explicit workflow. A system that continuously reads a cardiovascular biomarker and adjusts infusion to keep readings within a target band is closer.
Disease-state target (claim 8)
Claim 8 narrows the predetermined level of response to include reversible myocardial ischemia in the presence of coronary artery disease. This can function as an additional limitation. In practice:
- If a competitor does not aim to elicit ischemia reversibly in CAD, they may argue no literal satisfaction of claim 8.
- If their protocol targets a different endpoint (e.g., heart rate increase without ischemia), claim 8 may not read.
Transdermal iontophoretic closed-loop regimen (claim 2)
Claim 2 tightly ties:
- adaptive outcomes
- transdermal iontophoretic closed-loop infusion
- daily duration 0.5 to 4.0 hours
- treatment length 1 to 30 days
A competitor using oral beta-agonists or non-iontophoretic transdermals would likely avoid claim 2 even if they mimic exercise physiologically.
Chemical formula dependents (claims 3-5, 7, 11-13, 14-15, 16-19)
The formula-based dependents are leverage points for claim specificity:
- They require certain substituent combinations (X1/X2/Y1/Y2/Z, plus n = 2 or 3).
- They also include constraints like “not both hydrogen or carbamoyl,” and “one of Y1 and Y2 is hydrogen and the other is hydrogen or methyl,” with further cross-constraints (if Y1 is methyl, then X1 is not carbamoyl).
This yields a finite set of enumerated compound classes rather than open-ended beta-adrenergic activity.
Patent landscape mapping for enforcement strategy
What this patent likely blocks
Based on the claim structure alone, U.S. Patent 5,234,404 is positioned to restrict:
- Closed-loop beta-adrenergic delivery systems intended to mimic aerobic-exercise cardiovascular effects.
- Dose titration protocols where infusion is adjusted to maintain a predetermined physiological response range.
- Transdermal iontophoretic closed-loop regimens with specified daily treatment durations for adaptive outcomes.
- Specific beta-adrenergic compound variants within the claimed formula framework that are used in such systems.
How competitors can design around
Design-around paths suggested by the claim text:
- Use a beta-adrenergic agent but deliver it not via a closed-loop device (or not with monitoring + response-range maintenance as claimed).
- Use closed-loop delivery but not for “exercise simulating” outcomes comparable to aerobic activity, or not with the claimed immediate vs adaptive outcome framing.
- Avoid transdermal iontophoretic closed-loop infusion with the daily/hourly and day-count schedule tied to claim 2.
- Avoid specific substituent-defined compounds covered by formula dependents, using alternative beta-adrenergic agents outside the defined structural envelope.
Does the patent cover multiple drug classes or just specific compounds?
The independent claims are concept-driven (beta-adrenergic exercise simulation + closed-loop delivery). The dependent claims introduce formula constraints, so the patent has a two-tier structure:
- Broad concept claims (1 and 6) could be read on multiple beta-adrenergic compounds if they functionally satisfy “exercise simulating” and are delivered via closed-loop titration.
- Narrow composition claim dependents (3-5, 7, 11-13, 14-15, 16-19) capture specific chemical substitution patterns, which reduces the number of potential covered assets.
From an IP portfolio viewpoint, this structure is typical when the patentee wants coverage over both the system-method concept and certain specific chemical embodiments.
Key claim-by-claim scope table
| Claim |
Primary therapeutic goal |
Beta-adrenergic agent requirement |
Closed-loop requirement |
Device / route limits |
Extra clinical endpoint constraints |
| 1 |
Immediate cardiovascular responses similar to aerobic activity |
Yes (exercise simulating agent w/ beta-adrenergic activity) |
Yes (closed loop drug delivery device) |
Not limited |
None stated |
| 2 |
Adaptive cardiovascular + metabolic responses similar to aerobic activity |
Yes |
Yes |
Closed-loop transdermal iontophoretic infusion |
0.5 to 4.0 hours daily for 1 to 30 days |
| 3 |
Narrowed chemical set for claim 2 |
Formula-defined compound (X1/X2/Y1/Y2/Z, n=2 or 3) |
Inherited from claim 2 |
Inherited from claim 2 |
None stated |
| 4 |
Narrow chemical set |
Formula variant |
Inherited |
Inherited |
None stated |
| 5 |
Narrow chemical set |
Formula variant |
Inherited |
Inherited |
None stated |
| 6 |
Immediate cardiovascular responses similar to aerobic exercise |
Yes |
Yes (explicit monitoring + feedback) |
Closed-loop device; infusion into bloodstream |
Maintains response within predetermined range |
| 7 |
Immediate responses + compound formula |
Formula-defined compound |
Yes (from 6) |
Closed-loop device |
None stated beyond formula |
| 8 |
Immediate responses including ischemia endpoint |
Inherited |
Inherited |
Inherited |
Reversible myocardial ischemia in CAD presence |
| 9 |
As in claim 8 |
Inherited |
Inherited |
Closed-loop intravenous drug delivery |
CAD ischemia endpoint (from 8) |
| 10 |
As in claim 8 |
Inherited |
Inherited |
Closed-loop transdermal iontophoretic device |
CAD ischemia endpoint (from 8) |
| 11 |
Chemical narrowed set |
Z = hydroxy |
Inherited |
Inherited |
CAD ischemia endpoint (from 8) |
| 12 |
Chemical narrowed set |
X1/X2/Y1/Y2 and n specific |
Inherited |
Inherited |
CAD ischemia endpoint (from 8) |
| 13 |
Chemical narrowed set |
X1/X2/Y1/Y2 and n specific |
Inherited |
Inherited |
CAD ischemia endpoint (from 8) |
| 14 |
Increase cardiac contractility in depressed contractility |
Formula-defined compound or salt |
Not expressly device-specific |
Not specified |
Endpoint: depressed contractility |
| 15 |
Chemical narrowed set |
Specific X/Y/n |
Not specified |
Not specified |
Depressed contractility (from 14) |
| 16 |
Adaptive effects similar to aerobic exercise |
Formula-defined compound or salt |
Not device-specific in claim text |
Not specified |
“Adaptive effects” outcome framing |
| 17 |
Chemical narrowed set |
Specific substitution pattern |
Not specified |
Not specified |
Adaptive effects (from 16) |
| 18 |
Chemical narrowed set |
Specific substitution pattern |
Not specified |
Not specified |
Adaptive effects (from 16) |
| 19 |
Chemical narrowed set |
Specific substitution pattern |
Not specified |
Not specified |
Adaptive effects (from 16) |
How to interpret “closed-loop” in practical R&D and licensing
Claim 6’s explicit steps effectively define a feedback-control loop:
- establish a predetermined response range
- monitor cardiovascular responses
- adjust infusion to maintain the range
A system that reads real-time cardiovascular parameters (heart rate, pressure, ischemia markers, ECG-derived metrics) and adjusts beta-agonist infusion automatically meets the structure most directly. Systems that only titrate based on intermittent manual assessments or fixed dose schedules weaken mapping to claim 6’s “changing infusion as required” to maintain the monitored range.
For claim 2, transdermal iontophoretic infusion must be closed-loop for the adaptive regimen with the specified daily and multi-day window.
What “scope and claims” imply for a licensing or freedom-to-operate position
Most defensible licensing targets
- Licenses that cover beta-adrenergic “exercise simulation” methods using closed-loop titration.
- Licenses that cover closed-loop transdermal iontophoretic adaptive regimens with the explicit timing window.
- Licenses that cover specific formula-defined compound variants in claims 3-5, 7, 11-13, 14-15, 16-19.
Highest-risk commercialization scenarios
- A proprietary wearable or catheter-based closed-loop beta-agonist system designed to mimic aerobic cardiovascular effects.
- A product that targets CAD patients and aims to induce reversible myocardial ischemia as a controlled endpoint under closed-loop titration.
Key Takeaways
- Independent claim 1 and claim 6 hinge on beta-adrenergic “exercise simulating” pharmacology plus closed-loop delivery, with claim 6 also requiring monitoring and maintenance of a predetermined cardiovascular response range.
- Claim 2 is narrower and enforceable against specific platform choices: closed-loop transdermal iontophoretic infusion with 0.5 to 4.0 hours daily for 1 to 30 days.
- Dependent claims 7, 11-13, 14-15, 16-19 add formula-defined compound coverage, increasing infringement likelihood when competitors use substitution patterns inside the claimed chemical constraints.
- Claim 8 adds a clinical endpoint hook: reversible myocardial ischemia in CAD presence, which can narrow infringement to protocols that intentionally target that physiological effect.
FAQs
-
Does U.S. Patent 5,234,404 cover fixed-dose beta-agonist delivery without feedback control?
Claim 6 requires closed-loop monitoring and adjusting infusion to maintain a predetermined response range; fixed-dose regimens are less likely to satisfy that structure.
-
What makes claim 2 different from claim 1 and claim 6?
Claim 2 specifies closed-loop transdermal iontophoretic infusion and an explicit daily duration and treatment length.
-
Is the patent limited to intravenous administration?
No. It covers closed-loop delivery broadly, and dependent claims expressly include both intravenous (claim 9) and transdermal iontophoretic (claims 2 and 10) embodiments.
-
Do the formula-dependent claims require the exact listed substituent patterns?
Yes. Claims 3-5, 7, 11-13, 14-15, and 16-19 constrain the compounds via explicit substituent rules and values of n (2 or 3) plus cross-constraints among X, Y, and Z substituents.
-
How does claim 8 affect infringement analysis for CAD indications?
Claim 8 narrows the predetermined response to include reversible myocardial ischemia in the presence of CAD, so protocols not targeting that endpoint can be easier to position outside claim 8.
References
- United States Patent No. 5,234,404.
